| 1. |
- Gersen, Sander, et al.
(författare)
-
Detection of H2S, So2 and NO2 in CO2 at pressures ranging from 1- 40 bar by using broadband absorption spectroscopy in the UV/VIS range
- 2014
-
Ingår i: Energy Procedia. - : Elsevier BV. - 1876-6102. ; , s. 2570-2582
-
Konferensbidrag (refereegranskat)abstract
- This paper presents a methodology to quantitatively measure H2S, So2 and NO2 fractions in gaseous CO2 by using broadband absorption spectroscopy at 1 and 40 bar. The mole fractions of binary- And 3-component mixtures of H2S, So2 and NO2 in CO2 with known fractions ranging from 35-250 ppm are successfully derived from the measured absorption spectra. The difference between the fitted and experimental mole fractions is less than 10% for all studied mixtures. The results successfully demonstrate that low fractions of H2S, So2 and NO2 in gaseous CO2 can be accurately measured at pipeline conditions by using broad band absorption spectroscopy.
|
|
| 2. |
- van Essen, Martijn, et al.
(författare)
-
Neuroendocrine tumours : the role of imaging for diagnosis and therapy
- 2014
-
Ingår i: Nature Reviews Endocrinology. - : Springer Science and Business Media LLC. - 1759-5029 .- 1759-5037. ; 10:2, s. 102-114
-
Forskningsöversikt (refereegranskat)abstract
- In patients with neuroendocrine tumours (NETs), a combination of morphological imaging and nuclear medicine techniques is mandatory for primary tumour visualization, staging and evaluation of somatostatin receptor status. CT and MRI are well-suited for discerning small lesions that might escape detection by single photon emission tomography (SPECT) or PET, as well as for assessing the local invasiveness of the tumour or the response to therapy. Somatostatin receptor imaging, by (111)In-pentetreotide scintigraphy or PET with (68)Ga-labelled somatostatin analogues, frequently identifies additional lesions that are not visible on CT or MRI scans. Currently, somatostatin receptor scintigraphy with (111)In-pentetreotide is the more frequently available of the two techniques to determine somatostatin receptor expression and is needed to select patients for peptide receptor radionuclide therapy. In the future, because of its higher sensitivity, PET with (68)Ga-labelled somatostatin analogues is expected to replace somatostatin receptor scintigraphy. Whereas (18)F-FDG-PET is only used in high-grade neuroendocrine cancers, PET-CT with (18)F-dihydroxy-L-phenylalanine or (11)C-5-hydroxy-L-tryptophan is a useful problem-solving tool and could be considered for the evaluation of therapy response in the future. This article reviews the role of imaging for the diagnosis and management of intestinal and pancreatic NETs. Response evaluation and controversies in NET imaging will also be discussed.
|
|
